| Pair Name | Bufalin, MK2206 | ||
| Phytochemical Name | Bufalin (PubChem CID: 9547215 ) | ||
| Anticancer drug Name | MK2206 (PubChem CID: 46930998 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Bufalin, MK2206 | |||
| Disease Info | [ICD-11: 2A83.1] | Plasma cell myeloma | Investigative | |
| Gene Regulation | Up-regulation | Expression | AKT1 | hsa207 |
| In Vitro Model | NCI-H929 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_1600 |
| U266B1 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_0566 | |
| LP-1 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_0012 | |
| RPMI-8226 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_0014 | |
| Result | The data suggested that MK2206 significantly enhanced the cytocidal effects of bufalin in MM cells, regardless of the sensitivity to bortezomib, via the inhibition of the AKT/mTOR pathway. The study provided the basis of a promising treatment approach for MM. | |||
| No. | Title | Href |
|---|---|---|
| 1 | MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. Cell Death Dis. 2017 May 11;8(5):e2776. doi: 10.1038/cddis.2017.188. | Click |
